菏泽看癫痫著名的医院山东治疗小儿羊癫疯病的方法,烟台治癫痫那家医院比较好,济南癫痫病医院网上咨询,滨州癫痫病医院的位置,安徽癫痫病医院评论怎么样,全国哪里治癫痫专业,河北治疗羊羔疯病排名前十医院

BANGKOK, Nov. 4 (Xinhua) -- Hundreds of Bangkok residents gathered in the city centre on Thursday, making ten thousand micro-organism balls to help clean the polluted water in flooded areas.Organized by local volunteer groups, the activity aimed to make 10,000 Effective Micro-organism balls (EM Ball), which are proven to be efficient in cleaning contaminated floodwater.According to Danal Chanchaochai, the organizer of the event, people in flooded areas were facing critical conditions as germs may spread in polluted water and threat their health. Mainly consist of soil, rice bran and micro-organisms, a tennis-sized EM Ball is capable to clean up 10 liter of water and can last for as long as one month, which making it a perfect water sanitizer.Another main objective of the event was to educate citizens on the simple steps of making EM Balls, in case of more flood in the city, he said.The organization had generated buzz on social media sites like facebook and twitter, calling everyone to help.Held at Amarin Plaza, one shopping mall at city centre, the activity attracted groups of volunteers, including office workers, local students and even foreign visitors.Volunteers were lining up to get the raw materials from the collection point and gave back completed EM Balls to the distribution centre in boxes. Residents needed to present their identity cards in order to retrieve the donated water cleaners.Volunteer Kulawan Ayura Chai said that, although her house hadn' t been affected by water yet, she understood the difficult situation faced by the victims and felt responsible to help.Lasted for three days from Thursday to Saturday, the activity aimed to make 100,000 EM Balls, adding to the 30,000 balls made earlier, to distribute to the flood victims in Bangkok and other regions in Thailand.

WASHINGTON, Oct. 13 (Xinhua) -- U.S. researchers have corrected sickle cell disease in adult laboratory mice that had been bred to have the inherited blood disorder by activating production of a special blood component, according to a study published online Thursday in the journal Science.Sickle cell disease results from an abnormality in hemoglobin, the protein found in red blood cells that is responsible for transporting oxygen throughout the body. People living with sickle cell disease have two copies of an altered gene that produces sickle hemoglobin instead of normal adult hemoglobin. Sickle hemoglobin changes shape after releasing its oxygen, causing the red blood cell to become stiff, misshapen and sticky, and slowing blood flow to tissues. This process damages organs and causes pain.The study tested a new approach to increasing the production of a third form of hemoglobin -- fetal hemoglobin. Production of fetal hemoglobin predominates before birth, but turns off thereafter as adult hemoglobin production takes over. People with sickle cell disease are unable to make normal adult hemoglobin, and instead make sickle hemoglobin starting in infancy.An elevated level of fetal hemoglobin within the red blood cell reduces the tendency of sickle hemoglobin to change the shape of red blood cells. Considerable research has shown that the drug hydroxyurea increases production of fetal hemoglobin and reduces the number of pain crises and other complications of sickle cell disease in adults and children. However, not all patients respond well to hydroxyurea, and adverse side effects are a concern.The current study explores a more targeted approach to increasing fetal hemoglobin production. It builds upon earlier studies that discovered a protein called BCL11A normally suppresses the production of fetal hemoglobin soon after birth. The researchers viewed the BCL11A protein as a target for therapy and decided to see what would happen if they blocked production of the protein.The paper details how the research team silenced the mouse gene that produces the BCL11A protein in mice with sickle cell disease. Silencing the gene turned off production of the BCL11A protein and allowed the adult mice to continue to produce fetal hemoglobin. It appears to have eliminated disease symptoms without affecting other aspects of blood production."This discovery provides an important new target for future therapies in people with sickle cell disease," said Susan Shurin, acting director of the U.S. National Heart, Lung, and Blood Institute, which co-funded the study. "More work is needed before it will be possible to test such therapies in people, but this study demonstrates that the approach works in principle."Approximately 100,000 Americans live with sickle cell disease. It is most prevalent in people of African, Hispanic, Mediterranean, and Middle Eastern descent. There is no widely available cure for sickle cell disease. Bone marrow transplants have cured some patients, but the treatment is not without risk and most patients do not have relatives who can donate compatible and healthy bone marrow to them.

BEIJING, Sept. 29 (Xinhuanet) -- Even a slightly high blood pressure is considered dangerous to largely increase the stroke risk, a new study found.The finding was published Wednesday on the online edition of U.S. medical journal Neurology.In the study, researchers found people who have pre-hypertension, whose blood pressure measured between normal and high, are 55 percent more likely to suffer a stroke compared with normal people.The study involved data from 12 previous studies on blood pressure and stroke occurrence of some 500,000 adults.About one in three U.S. adults suffer from pre-hypertension, which is defined at a systolic blood pressure between 120 and 139 or a diastolic blood pressure between 80 and 89, according to the U.S. Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure."People who do fall into the higher range of pre-hypertension should modify their lifestyle as much as possible," suggested Dr. Bruce Ovbiagele, director of the Olive View-UCLA Stroke Program and leading author of the study.Stroke is the number three cause of death, killing more than 130,000 in the U.S. a year, according to a CBS report.

WASHINGTON, Nov. 18 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday approved Erwinaze to treat patients with acute lymphoblastic leukemia (ALL), who have developed an allergy to E. coli derived asparaginase and pegapargase chemotherapy drugs used to treat ALL.Acute lymphoblastic leukemia is a type of cancer in which the bone marrow makes too many lymphocytes, a type of white blood cell. White blood cells help the body fight infection and are formed in the bone marrow.Erwinaze is injected directly into the muscle three times a week and works by breaking down one of the body's protein building blocks (the amino acid, asparagine) that is present in the blood, and is necessary for the growth of all cells. Leukemia cells cannot produce this protein building block. When a patient is treated with Erwinaze the leukemia cells die. Normal human cells are able to make enough asparagine for their own needs through biosynthesis and will not be affected by treatment with Erwinaze."The approval of Erwinaze underscores the FDA's commitment to the approval of drugs for conditions with limited patient populations with unmet medical needs using novel trial endpoints," said Richard Pazdur, director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research.Side effects associated with Erwinaze treatment include serious allergic reactions, inflammation of the pancreas, high blood levels of liver enzymes, blood clotting, bleeding, nausea, vomiting and high blood sugar.

SAN FRANCISCO, Nov. 3 (Xinhua) -- Computer chipmaker Advanced Micro Devices Inc. (AMD) on Thursday said it plans to cut its global workforce by about 10 percent in a move to reduce operational costs.The layoff will occur across all functions globally and is expected to be substantially completed by the end of the first quarter of 2012, the company said.The cuts will amount to about 1,400 jobs, according to estimates by analysts.Combined with implementing efficiencies across the company's operations, AMD expected that the workforce reduction will result in operational savings of more than 200 million U.S. dollars in 2012."Reducing our cost structure and focusing our global workforce on key growth opportunities will strengthen AMD's competitiveness and allow us to aggressively pursue a balanced set of strategic activities designed to accelerate future growth," Rory Read, AMD's chief executive officer, said in a statement.As the world's second largest maker of processors for computers, AMD has been suffering from the slowdown of global PC market and is seen as slow to move into new mobile device market.The operational savings will help accelerate the company's future growth in lower power, emerging markets and in the cloud computing field, AMD said.